Accompanying p53 mutations on tumor progression, mutant p53 is detained in cytoplasm and loses its transactivation activity and the binding capability with Bcl-2 family proteins, instead, acquiring the autophagy-inhibitory action [36, 39], which leads to the tumor survival. This evidence concerns the gene BCL2 and neoplasm.